HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC

Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. A prospective study was conducted on the data of locally advanced unresectable ICC patients receiving GC-HAIC combined with immunosuppressive therapy, evaluating the treatment efficacy and safety.

NCT Number	NCT07364305
Lead Sponsor	Eastern Hepatobiliary Surgery Hospital
Conditions	ICC, Advanced Cancer
Enrollment	50 participants
Start Date	2025-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-23